文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT在前列腺癌生化复发且PSA≤0.2 ng/mL患者中的应用:德国多中心分析涵盖[68Ga]Ga-PSMA-11、[68Ga]Ga-PSMA I&T与[18F]PSMA-1007等常规PSMA示踪剂

PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-30

该德国五中心研究分析321例生化复发且PSA≤0.2 ng/mL的前列腺癌患者,比较三种PSMA示踪剂的检出率。总体合并检出率为29.6%,三种示踪剂间无统计学显著差异。PSA>0.15 ng/mL、初始Gleason评分>7及接受雄激素剥夺治疗者检出率显著更高。

要点

  • 321例PSA≤0.2 ng/mL生化复发患者中,PSMA PET/CT总体合并检出率为29.6%。
  • 三种示踪剂检出率无统计学显著差异:[68Ga]Ga-PSMA-11 29.4% vs [68Ga]Ga-PSMA I&T 22.5% vs [18F]PSMA-1007 32.4%,p≥0.314。
  • PSA>0.15 ng/mL、初始Gleason评分>7及接受雄激素剥夺治疗者检出率显著更高。

核心结论

  • 三种示踪剂在本研究样本中诊断性能相当,68Ga与18F标记示踪剂间未见显著优效性,总体合并检出率为29.6%。
  • 该阳性率可作为医生和患者在低PSA值情况下的预期参考。
  • 需要更大队列、最好为前瞻性设置的研究来确认和扩展本研究发现。

研究设计与样本

  • 德国五家学术中心的多中心研究,分析321例生化复发且PSA≤0.2 ng/mL的前列腺癌患者。
  • 使用三种PSMA靶向放射性示踪剂:[68Ga]Ga-PSMA-11、[68Ga]Ga-PSMA I&T和[18F]PSMA-1007,分析检出率及潜在预测参数。

主要发现

  • 总体合并检出率为29.6%。
  • 三种示踪剂间检出率无统计学显著差异:[68Ga]Ga-PSMA-11 29.4% vs [68Ga]Ga-PSMA I&T 22.5% vs [18F]PSMA-1007 32.4%,p≥0.314。
  • PSA水平>0.15 ng/mL患者检出率显著更高(p=0.029,φ=0.122)。
  • 初始Gleason评分>7患者检出率显著更高(p=0.018,φ=0.141)。
  • 接受雄激素剥夺治疗患者检出率显著更高(p=0.031,φ=0.120)。

关键数值与推荐

  • 总体合并检出率29.6%。
  • [68Ga]Ga-PSMA-11检出率29.4%,[68Ga]Ga-PSMA I&T检出率22.5%,[18F]PSMA-1007检出率32.4%,组间比较p≥0.314。
  • PSA>0.15 ng/mL组检出率显著高于PSA≤0.15 ng/mL组(p=0.029,φ=0.122)。
  • 初始Gleason评分>7组检出率显著高于≤7组(p=0.018,φ=0.141)。
  • 接受雄激素剥夺治疗组检出率显著高于未接受组(p=0.031,φ=0.120)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大队列、最好为前瞻性设置的研究来确认和扩展本研究发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET/CT at very low PSA values (≤ 0.2 ng/mL) remain limited. METHODS: In this multicenter study, we analyzed 321 patients with BCR and a PSA value ≤ 0.2 ng/mL across five German academic centers, using three different PSMA-targeted radiotracers: [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007 and analyzed the detection rates and potential predictive parameters. RESULTS: The overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([68Ga]Ga-PSMA-11 29.4% vs. [68Ga]Ga-PSMA I&T, 22.5% vs. [18F]PSMA-1007 32.4%, p ≥ 0.314). Detection rates were significantly higher in patients with a PSA level > 0.15 ng/mL (p = 0.029, φ = 0.122), in those with an initial Gleason score > 7 (p = 0.018, φ = 0.141) and in those receiving androgen deprivation therapy (p = 0.031, φ = 0.120). CONCLUSION: All three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the 68Ga- and 18F-labeled tracers in the patient sample investigated (overall pooled detection rate: 29.6%). This positivity rate can serve as an expectation horizon for both the attending physician and the patient in the case of low PSA values. Further studies with larger cohorts, preferably conducted in a prospective setting, are needed to confirm and expand upon our findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Burgard C, Frei M, Blickle A, et al. PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025. PMID: 40304782. doi:10.1007/s00259-025-07292-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。